Allergen-specific immunotherapy in rhinitis patients is associated with milder COVID-19 symptoms and improved quality of life
Hanqiao Li, Renkang Wang, Benquan Yu, Jun He, Yibo Hu, Zuozhong Xie, Zi'an Xiao · 2026
Read Allergen-specific immunotherapy in rhinitis patients is associated with milder COVID-19 symptoms and improved quality of life by Hanqiao Li, Renkang Wang, Benquan Yu, Jun He, Yibo Hu, Zuozhong Xie, Zi'an Xiao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13224361.txt.
Description
Hanqiao Li and co-authors report a 2026 Chinese cohort study of allergy patients who caught COVID-19 after lockdowns ended. Allergic rhinitis causes sneezing, congestion, and a runny nose, and its only treatment that changes the disease course is allergen-specific immunotherapy, a long course of controlled allergen doses. The question was whether that immune training also softened a later coronavirus infection.
Patients receiving immunotherapy faced lower risk of smell loss and sore throat once infected. Their whole-body symptoms also ended sooner, and their quality of life scored better than that of comparable patients. The authors read the pattern as a first signal that this immune modulation may extend protection beyond the original allergy.
Catalog record
| CREATOR | Hanqiao Li, Renkang Wang, Benquan Yu, Jun He, Yibo Hu, Zuozhong Xie, Zi'an Xiao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |